$ABT (Abbott Laboratories)

$ABT {{ '2016-05-27T16:17:02+0000' | timeago}} • SEC

In April 2016, $ABT obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $17.2Bil in conjunction with its pending acquisition of $STJ. While $ABT plans to fund the cash portion of this deal with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$ABT {{ '2017-06-16T10:42:39+0000' | timeago}} • Announcement

$ABT announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific.

$ABT {{ '2017-06-09T14:38:24+0000' | timeago}} • Announcement

The Board of $ABT declared a quarterly common dividend of 26.5 cents per share. The dividend is payable Aug. 15, 2017, to shareholders of record as on July 14, 2017.

$ABT {{ '2017-04-19T14:38:44+0000' | timeago}} • Webcast

$ABT said its results were slightly impacted by the demonetization in India and the impact is now diminishing. With respect to the Goods and Services Tax, the government is looking at implementing a new tax scheme. If this is done, it could have an impact on the way distributors manage inventory. $ABT is monitoring this situation.

$ABT {{ '2017-04-19T14:16:27+0000' | timeago}} • Webcast

$ABT said its Nutrition business is driven by emerging markets and generates solid profit and cash flow. In Pharma, the branded generic business is in strong position and the company is focused on markets where high double digit growth exists. Diagnostics is launching a huge range of new systems and products. $ABT is pleased with its portfolio.

$ABT {{ '2017-04-19T13:56:43+0000' | timeago}} • Webcast

$ABT said there are some steps pending for the closure of its merger with $ALR. $ALR has to file its Form 10-K while $ABT has to divest a couple of its businesses to gain regulatory approvals. $ABT expects to close the transaction by 3Q17-end. Some businesses will be divested after the merger and the amount of sales and profits will change.

$ABT {{ '2017-04-19T12:20:16+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphics: Q1 2017 highlights

$ABT {{ '2017-04-19T12:10:04+0000' | timeago}} • Announcement

$ABT continues to expect 2017 EPS from continuing operations of $0.92-1.02, including intangible amortization and integration expenses related to the acquisition of St. Jude Medical. Excluding specified items, projected full-year 2017 adjusted EPS from continuing operations remains unchanged at $2.40-2.50.

$ABT {{ '2017-04-19T12:07:45+0000' | timeago}} • Announcement

$ABT reported a 32.5% jump in 1Q17 earnings driven by gain from the sale of the AMO business. Net income rose to $419MM or $0.24 per share from $316MM or $0.21 per share last year. Adjusted EPS increased to $0.48 from $0.41. Net sales grew to $6.34Bil from $4.89Bil. On a comparable operational basis, worldwide sales increased 3.2%.

$JNJ {{ '2017-02-27T14:41:59+0000' | timeago}} • Announcement

$JNJ completed the acquisition of Abbott Medical Optics (AMO), a subsidiary of $ABT. The all-cash $4.325Bil acquisition includes ophthalmic products in 3 areas of patient care: cataract surgery, laser refractive surgery and consumer eye health. The combined will operate under the brand name Johnson & Johnson Vision.

$ABT {{ '2017-02-21T18:13:27+0000' | timeago}} • Announcement

$ABT commenced offers to exchange all validly tendered and accepted notes of the following series issued by St. Jude Medical, LLC for notes to be issued by $ABT. The exchange offers and consent solicitations will expire on March 20, 2017, unless extended or terminated.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
INVA (Innoviva, Inc.)
Thursday, April 27 2017 - 9:00pm
CYTK (Cytokinetics, Incorporated)
Thursday, April 27 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ABAX (Abaxis, Inc.)
Thursday, April 27 2017 - 8:15pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm

AlphaGraphics you may like